Mir-375 Explained

mir-375
Symbol:mir-375
Rfam:RF00700
Mirbase Family:MIPF0000114
Rna Type:microRNA
Tax Domain:Eukaryota

The miR-375 microRNA (miRNA) is a short RNA molecule located on human chromosome 2 in between the CRYBA2 and CCDC108 genes.[1] miRNAs are small (18–25 nucleotides), non-coding RNAs that regulate genes post-transcriptionally by inhibiting translation and/or causing mRNA degradation.[1] miR-375 is specifically expressed in the pancreatic islets, brain and spinal cord.[2] [3]  Genetic manipulation of miR-375 levels can decrease cancer development and autoimmunity in affected cell types.

Roles in Development

Diabetes

miR-375 plays a critical role in diabetes by regulating the expression of related genes involved in pancreatic islet formation, pancreatic development, and β-cell secretion.[4] These processes are related to diabetes because pancreatic islets contain β-cells that produce insulin, a hormone that regulates blood sugar.[5] A person with diabetes will have high blood sugar either because their cells are not responding to insulin or because their pancreatic beta cells are not producing enough of it. In patients with type 2 diabetes, β-cell mass is reduced by up to 60% when compared to healthy individuals.[6] Similarly, there is a decrease in β-cell mass per pancreatic area when miR-375 is knocked out in mice.[7] In addition, miR-375 shows elevated expression levels during pancreatic development, which coincide with higher insulin expression and β-cell proliferation. Thus, evidence suggests that miR-375 is important for normal pancreatic islet formation and insulin secretion from β-cells. Because of the role miR-375 plays in regulating processes essential for healthy sugar metabolism, it may be a potential target for treating diabetes.

Diabetes is currently managed with exogenous insulin and islet cell transplantation. However, these treatments fall short in their attempts to reestablish the natural regulation of blood sugar and are limited by the scarcity of donor tissue, respectively. To address these concerns, scientists have begun investigating the potential of human embryonic stem cells (hESCs), which are cells that can develop into many adult cell types including pancreatic β-cells. As such, hESCs have the potential to provide a limitless source of insulin-producing β-cells. However, creating mature β-cells from hESCs has proved challenging for researchers because the hESC-derived cells often secreted other hormones in addition to insulin. miR-375 may provide a new way to mature hESCs into β-cells because of its high expressivity in β-cells and its function in insulin release. Therefore, miR-375 is a promising target for the treatment of diabetes.

Roles in Cancer

Affected organProposed mechanisms/applications
LiverIn cancerous liver cells, known as hepatocellular carcinomas (HCC), miR-375 acts as a tumour suppressor. This was evidenced by a decrease in the rate of uncontrolled cell division through the inhibition of a well-known oncogene, AEG-1, in response to miR-375 overexpression.[8] Recent studies show that when miR-375 is introduced into HCC cell lines, there is a reduction in cell proliferation, motility, and migration, as well as an increase in apoptosis in vitro.[9] [10] [11] In vivo studies in mouse models of HCC also show reduced tumour growth with no apparent side effects. These results support potential strategies to increase miR-375 levels in HCCs to prevent metastasis.
EsophagusmiR-375 overexpression inhibits tumour growth and metastasis of esophageal cancer cells by inhibiting insulin-like growth factor 1 receptor and proteins involved in the PI3K/Akt signalling pathway.[12] The PI3K/Akt signalling pathway promotes aerobic glycolysis, which is a hallmark of rapidly dividing cancer cells. Hence, a potential strategy for inhibiting proliferation in esophageal cancer cells would be to increase intracellular miR-375 levels.
SkinIncreased expression of miR-375 in Merkel cell carcinomas (MCC) is used as a marker to differentiate MCC from other common skin cancers.[13]

Immunity

miR-375 is involved in many autoimmune diseases, such as inflammatory bowel diseases (IBD) and type 1 diabetes mellitus (T1DM). For instance, miR-375 can be used as a factor to distinguish between the different types of IBD (e.g. Crohn's disease vs ulcerative colitis).[14] In patients with T1DM, miR-375 dysregulation was observed in a number of tissues that were directly linked to the development of the disease.[15] Furthermore, miR-375 is involved in the molecular aspects of immunity as miR-375 silencing decreases the production of pro-inflammatory macrophages and subsequent inflammatory response.[16] While pro-inflammatory macrophages are responsible for killing pathogens, a sustained pro-inflammatory response leads to a long list of disorders (e.g. arthritis, asthma, atherosclerosis, blindness, cancer, and diabetes).[17]

Since miR-375 silencing inhibits the production of pro-inflammatory macrophages, it can delay the onset of atherosclerosis (the main underlying cause of heart attacks and strokes) in mice, indicating its therapeutic potential in conditions accompanied by chronic inflammation.[16] Interestingly, miR-375 enhances macrophage migration into cancer cells by targeting PNX and TSN3, which are both proteins involved maintaining cell structure and organization.[18]

See also

Further reading

Notes and References

  1. Baroukh . Nadine N. . Van Obberghen . Emmanuel . Function of microRNA-375 and microRNA-124a in pancreas and brain: Function of miR-375 and 124a in pancreas and brain . FEBS Journal . November 2009 . 276 . 22 . 6509–6521 . 10.1111/j.1742-4658.2009.07353.x. 20102393 . 45784402 . free .
  2. Avnit-Sagi . Tali . Kantorovich . Lia . Kredo-Russo . Sharon . Hornstein . Eran . Walker . Michael D. . The Promoter of the pri-miR-375 Gene Directs Expression Selectively to the Endocrine Pancreas . PLOS ONE . 3 April 2009 . 4 . 4 . e5033 . 10.1371/journal.pone.0005033. 19343226 . 2660411 . free .
  3. Bhinge . Akshay . Namboori . Seema C. . Bithell . Angela . Soldati . Chiara . Buckley . Noel J. . Stanton . Lawrence W. . MiR-375 is Essential for Human Spinal Motor Neuron Development and May Be Involved in Motor Neuron Degeneration . Stem Cells . 1 January 2016 . 34 . 1 . 124–134 . 10.1002/stem.2233. 26507573 . 26250020 . free .
  4. Liu . Yang . Wang . Qiuyuan . Wen . Jie . Wu . Yiru . Man . Chaolai . 2021-06-15 . MiR-375: A novel multifunctional regulator . Life Sciences . en . 275 . 119323 . 10.1016/j.lfs.2021.119323 . 33744323 . 232309025 . 0024-3205.
  5. Li . Xueling . 2014-01-01 . miR-375, a microRNA related to diabetes . Gene . en . 533 . 1 . 1–4 . 10.1016/j.gene.2013.09.105 . 24120394 . 0378-1119.
  6. Wysham . Carol . Shubrook . Jay . 2020-11-16 . Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications . Postgraduate Medicine . 132 . 8 . 676–686 . 10.1080/00325481.2020.1771047 . 0032-5481 . 32543261. 219705786 . free .
  7. Poy . Matthew N. . Hausser . Jean . Trajkovski . Mirko . Braun . Matthias . Collins . Stephan . Rorsman . Patrik . Zavolan . Mihaela . Stoffel . Markus . 2009-04-07 . miR-375 maintains normal pancreatic α- and β-cell mass . Proceedings of the National Academy of Sciences . en . 106 . 14 . 5813–5818 . 10.1073/pnas.0810550106 . 0027-8424 . 2656556 . 19289822. 2009PNAS..106.5813P . free .
  8. He . X.-X. . Chang . Y. . Meng . F.-Y. . Wang . M.-Y. . Xie . Q.-H. . Tang . F. . Li . P.-Y. . Song . Y.-H. . Lin . J.-S. . July 2012 . MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo . Oncogene . en . 31 . 28 . 3357–3369 . 10.1038/onc.2011.500 . 22056881 . 2050305 . 1476-5594. free .
  9. Xue . Hui-Ying . Liu . Yong . Liao . Jia-Zhi . Lin . Ju-Sheng . Li . Bin . Yuan . Wei-Gang . Lee . Robert J. . Li . Lei . Xu . Chuan-Rui . He . Xing-Xing . 2016-12-27 . Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma . Oncotarget . en . 7 . 52 . 86675–86686 . 10.18632/oncotarget.13431 . 1949-2553 . 5349944 . 27880727.
  10. Fan . Yin-Ping . Liao . Jia-Zhi . Lu . Ya-Qi . Tian . De-An . Ye . Feng . Zhao . Peng-Xuan . Xiang . Guang-Ya . Tang . Wang-Xian . He . Xing-Xing . June 2017 . MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma . Molecular Therapy - Nucleic Acids . en . 7 . 181–189 . 10.1016/j.omtn.2017.03.010. 28624193 . 5415965 . 42833717 .
  11. Zhao . Pengxuan . Li . Minsi . Wang . Yao . Chen . Yan . He . Chuanchuan . Zhang . Xiaojuan . Yang . Tan . Lu . Yao . You . Jia . Lee . Robert J. . Xiang . Guangya . 2018-05-01 . Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles . Acta Biomaterialia . en . 72 . 248–255 . 10.1016/j.actbio.2018.03.022 . 29555460 . 1742-7061.
  12. Kong . Kar Lok . Kwong . Dora Lai Wan . Chan . Tim Hon-Man . Law . Simon Ying-Kit . Chen . Leilei . Li . Yan . Qin . Yan-Ru . Guan . Xin-Yuan . MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor . Gut . 1 January 2012 . 61 . 1 . 33–42 . 10.1136/gutjnl-2011-300178 . 21813472 . 36516750 . 10722/144525 . free .
  13. Renwick . Neil . Cekan . Pavol . Masry . Paul A. . McGeary . Sean E. . Miller . Jason B. . Hafner . Markus . Li . Zhen . Mihailovic . Aleksandra . Morozov . Pavel . Brown . Miguel . Gogakos . Tasos . Mobin . Mehrpouya B. . Snorrason . Einar L. . Feilotter . Harriet E. . Zhang . Xiao . Perlis . Clifford S. . Wu . Hong . Suárez-Fariñas . Mayte . Feng . Huichen . Shuda . Masahiro . Moore . Patrick S. . Tron . Victor A. . Chang . Yuan . Tuschl . Thomas . Multicolor microRNA FISH effectively differentiates tumor types . Journal of Clinical Investigation . 3 June 2013 . 123 . 6 . 2694–2702 . 10.1172/JCI68760. 23728175 . 3668843 .
  14. Schaefer . Jeremy S . Attumi . Taraq . Opekun . Antone R . Abraham . Bincy . Hou . Jason . Shelby . Harold . Graham . David Y . Streckfus . Charles . Klein . John R . December 2015 . MicroRNA signatures differentiate Crohn's disease from ulcerative colitis . BMC Immunology . en . 16 . 1 . 5 . 10.1186/s12865-015-0069-0 . 1471-2172 . 4335694 . 25886994 . free .
  15. Assmann . Taís S . Recamonde-Mendoza . Mariana . De Souza . Bianca M . Crispim . Daisy . November 2017 . MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis . Endocrine Connections . 6 . 8 . 773–790 . 10.1530/ec-17-0248 . 28986402 . 5682418 . 2049-3614.
  16. Qiu . Yanyan . Xu . Jinyi . Yang . Lihong . Zhao . Guihua . Ding . Jing . Chen . Qiong . Zhang . Na . Yang . Ruike . Wang . Jijing . Li . Shuaibing . Zhang . Luming . March 2021 . MiR-375 silencing attenuates pro-inflammatory macrophage response and foam cell formation by targeting KLF4 . Experimental Cell Research . en . 400 . 1 . 112507 . 10.1016/j.yexcr.2021.112507. 33545131 . 231963270 .
  17. Redka . Dar’ya S. . Gütschow . Michael . Grinstein . Sergio . Canton . Johnathan . 2018-01-01 . Differential ability of proinflammatory and anti-inflammatory macrophages to perform macropinocytosis . Molecular Biology of the Cell . 29 . 1 . 53–65 . 10.1091/mbc.E17-06-0419 . 1059-1524 . 5746066 . 29093026.
  18. Frank . Ann-Christin . Ebersberger . Stefanie . Fink . Annika F. . Lampe . Sebastian . Weigert . Andreas . Schmid . Tobias . Ebersberger . Ingo . Syed . Shahzad Nawaz . Brüne . Bernhard . 2019-03-08 . Apoptotic tumor cell-derived microRNA-375 uses CD36 to alter the tumor-associated macrophage phenotype . Nature Communications . 10 . 1 . 1135 . 10.1038/s41467-019-08989-2 . 2041-1723 . 6408494 . 30850595.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mir-375".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.